Usher broke down in court as he gave evidence during a legal battle with his ex-wife over custody of their two sons.

Usher Raymond IV and his ex-wife Tameka Foster-Taymond are battling over custody of their two kids. Tameka wants full custody. Usher wants increased visitation.

On the stand, Usher testified about his ex going through nanny after nanny and said he worries about who is caring for his kids.

Usher also testified Tameka has a violent history. On the stand he said she sent a threatening email to a friend of his and later attacked her. 

The couple married in 2007. Their marriage lasted less than two years.





Source:cbsatlanta.com

Fabio Capello has held preliminary talks with Liverpool

Fabio Capello has held talks with Liverpool and has been invited to meet with owners Fenway Sports Group.

Roberto Martinez and Andre Villas-Boas have also held meetings with Liverpool and are on the list speak to the owners, and it is expected that they will be joined by at least one other candidate.

A source told ESPN: “The long list of candidates is now narrowing down to a workable number who are likely to go to Boston, although there is of course a chance that the owners will come over here to see the candidates.”

Capello, who still has a home in West London, had ideally sought the Chelsea job, but the Blues have made no contact with the former England boss and the Italian has now ruled himself out of the Chelsea equation.

However, an agent representing Liverpool did approach Capello before the Champions League final to enquire as to his interest in the position. He has since held preliminary talks, at which he expressed a desire to be considered, and will now hold a more formal discussion.

Several coaches on Liverpool’s ‘long list’ have ruled themselves out of the running, including Frank de Boer, Jurgen Klopp and Brendan Rodgers, while Didier Deschamps has said he expects to stay at Marseille.

Liverpool fan group Spirit of Shankly, which led the protests against former owners Tom Hicks and George Gillett, has written to Fenway Sports Group to express its concern over the way the club is being run.

“It may be that yourselves and the board of Liverpool Football Club have a vision you are working towards,” SOS’s letter read. “It may be that you have implemented a strategy to deliver that vision and decisions are being made to work towards this.

“However, from the outside, where supporters find themselves once again, it looks like a football club in disarray. Confusion and chaos seems to reign and no one is coming out of this with much credit, particularly the football club’s image and brand.

“We need clear and pro-active communication, a confident message about the club’s plans that breeds confidence amongst supporters that we are moving in the right direction. Instead, we have silence and a lack of information or understanding on decisions being made.

“As supporters we have seen all too clearly what a lack of communication from absentee owners leads to. Ultimately supporters remain in the dark once again about the plans for this football club moving forward.

“We find ourselves experiencing deja vu, where boardroom decisions lead to more questions than they answer. We ask that you speak with supporters – engage with a true representative cross section of supporters and work with supporters to provide solutions to our current problems.”—ESPN

Didier Drogba and Fernando Torres celebrate the club's Champions League success

Chelsea chief executive, Ron Gourlay, has calmed suggestions Didier Drogba and Fernando Torres will leave the club.

Drogba, 34, had been quoted in France Football as saying he had “decided to leave” Stamford Bridge, but his agent later said the quotes were “not genuine”.

Following the Champions League success, Chelsea had revealed that talks were to take place this week over a contract extension for Drogba, and it appears nothing has changed on that front.

“Conversations with Didier have been going on for months and still are,” Gourlay told Chelsea TV. “He’s made it clear he loves Chelsea and loves everything he’s achieved at the club. Once we’re ready to make an announcement, we’ll do so.”

Torres, meanwhile, had given an interview to journalist Guillem Balague in the wake of the victory over Bayern Munich on Saturday revealing he was unhappy with his lack of playing time and would seek talks over his future.

Balague subsequently wrote on his Twitter account that the quotes did not mean that Torres wanted to leave the club, and Gourlay has indicated that the Blues are untroubled by his comments.

“Torres came on when we were behind and played a big part to help us win the Champions League,” Gourlay said. “I’d be surprised if Fernando, who’s been awesome, didn’t want more time on the field, every player does.”

He added: “It was the biggest game in our history so there were different levels of emotions all over the pitch – you have to take these things into account.”

The future of interim manager Roberto Di Matteo is also the subject of speculation – indeed, the Daily Star carried quotes from a source close to Roman Abramovich on Tuesday morning suggesting he is unlikely to be given the job.

“Roman thinks Di Matteo has been very, very lucky and that he made a lot of mistakes in the games he’s been in charge, with his tactics and selections,” the source said. “The statistics in the two games against Barcelona and the final show just how lucky Di Matteo was. Roman has to decide this week and he will not care what the public thinks. Roman did not become a billionaire worrying about public opinion – he only cares about what is right for the club.”

Gourlay, though, was giving nothing away about the club’s plans.

“We now need to sit down over the next week or two, or however long it takes, because we have to do what’s right for the club,” Gourlay said. “I know the fans will be pushing for Robbie. We’re going to look at the season, look at what worked for us, look at the mistakes we made and put them right and take it forward.”—ESPN

Thiago Silva and Zlatan Ibrahimovic are set to stay at AC Milan

AC Milan boss, Massimiliano Allegri, has dismissed speculation that Zlatan Ibrahimovic and Thiago Silva could be sold after Roberto Mancini paid a visit to the club.

Mancini was seen at Milan headquarters on Monday, where he held a 30-minute meeting with Rossoneri vice-president Adriano Galliani. The Manchester City boss played down the talks, describing it as nothing more than a courtesy visit and adding: “Milan fans can stay calm.” Nonetheless, speculation has been rife over the content of the discussions.

City have long been linked with a move for Ibrahimovic, who worked under Mancini at Inter Milan, but Gazzetta dello Sport, Tuttosport and Corriere dello Sport were all reporting on Tuesday morning that the meeting was to discuss a potential deal to sign defender Thiago Silva. Potential swap deals involving Mario Balotelli and Carlos Tevez have also been suggested.

However, Allegri insists Milan will not allow their key players to depart, with the club looking to build after a disappointing season in which they won only the Supercoppa Italiana.

“The club and the president are keen to maintain AC Milan at a high level,” Allegri told the AC Milan television station. “Ibrahimovic and Thiago will remain here.

“Thiago is young and Ibrahimovic can also give a lot. They are two champions on which Milan can build its basis for the future. The club is only working on replacing those players that have left.”—ESPN

Mr Emmanuel Kofi Buah (left), Ghana’s deputy Energy Minister, being presented with his award by the organisers

STORY BY: EVANS OSEI BAFFOUR, BACK FROM HOUSTON, TEXAS, USA.

A Ghanaian deputy Minister of Energy in charge of Petroleum, Mr Emmanuel Armah-Kofi Buah, has been honoured with the State of Texas recognition award at the fifth edition of the Offshore Technology Conference (OTC) held in Houston, Texas USA.

The meritorious award is for his commitment to ensure the creation of a sustainable energy policy in the sub-Saharan region.

According to organisers of this year’s event, the award was given based on Mr Buah’s contribution towards the development and stimulation of economic growth in the oil and gas sector over the past few years as a Minister responsible for the sector.

They added that the Ghanaian minister deserved the award due to his youthful exuberance which has necessitated the rapid growth of his country’s oil sector.

They intimated that he ensured that the best laid down policies were duly formulated and implemented.

His Excellency Gabriel Obiang Lima, the Minister responsible for Mining, Industry and Energy from the Equatorial Guinea, also won the Rising Star award and was decorated with the Dynamic Regional Leadership award.

Other award winners were Dr Keith Milheim, Director of Meps-First Oil, who won an award for his technological inventions in the development of riser as disruptive deep water drilling technologies; Tullow Oil, represented by Tim O’Hanlon, and the Vice President for African business, was given an award for discovering oil and gas in most of the region’s new frontiers.

The trio of Dr Nirajan Banik, Scientific Advisor of Western Geco Schlumberger; Mark Miyaoka, CEO of Terradata Geoscience, and; Dr Jim Spear, won the awards for Research and development in the oil and gas industry.

Ecobank also received an award for its prime involvement in regional oil and gas financing and for her buoyant market expansion as a differentiated pan-African bank.

At the end of the event, participants, exhibitors, sponsors, media partners and a great array of the members of the fourth realm of estate are looking forward to another fruitful mix in the 6th annual sub-Saharan Africa Oil and Gas Conference which has been scheduled to come off in Houston from Thursday, April 25 – Friday, April 26, 2013.

Michael Ikpoki, CEO of MTN

The chiefs and people of Juaso Nkyesa in the Asante Akim District of Ashanti Region have expressed appreciation to Mobile Telecommunications Network (MTN) for what they see as a huge boost to education in the area.

Their appreciation follows the construction of a six-unit classroom block with store and offices for teachers of the Nkyesa LA Primary School.

The commissioning of the new classroom block has brought a great relief to both young and old in the community since school pupils hitherto had only an old school block built in 1960s to be used as a classroom, a situation which negatively impacted on teaching and learning in the area.

The commissioning formed part of series of activities marking the MTN Ashantifest which was celebrated last week.

At a brief ceremony to commission the project, Chief Executive Officer of MTN, Michael Ikpoki, reiterated the company’s urge to help in contributing to the socio economic development of the country adding that education has always been a priority of MTN.

He announced that apart from the GH¢162,318 million cedis being the cost of the project, MTN also provided an additional GH¢10,000 which was used for furnishing the classrooms.

Mr Ikpoki who revealed that the Nkyesa Primary School was the third school to be commissioned by MTN within four months also added that the benefits of education to a nation could not be over emphasised hence their commitment to helping several villages in the country with educational facilities.

He stated that the company had assisted in constructing 32 educational projects in the country costing them about GH¢4.7 million cedis.

“Let me also add that of this amount Ashanti Region alone has enjoyed GH¢700, 000 in health and educational projects but we are not done yet, there is more to follow and we look forward to continued support from all chiefs and people in future,” the MTN CEO said.

The Chief of Nkyesa, Nana Nkyesa Frimpong Charles, in an address read on his behalf could not hide his joy at the commissioning of the school and asked for God’s blessings for staff of the telecom company.

He however asked for more support from MTN in the construction of boreholes and a chief’s palace.

He advised parents in the village to ensure that their wards attend school regularly since ‘the future of Nkyesa lies with these kids.’

STORY: FROM JAMES APPIAKORANG JNR., NKYESA, A/R.

The 2012 edition of the Offshore Technology Conference (OTC) held in Houston, Texas in the United States of America (USA) came to a resounding end with many bright spots to look up to.

During a Pan-African programme at the fifth sub-Saharan Africa Oil & Gas Conference held at the forecourt of Reliant Arena–OTC venue in Houston, Texas, the Chief Executive Officer of Energy and Corporate Africa, Mr Sunny Oputa, the organisers of the event, noted that “a conference like this is needed to promote the new and promising African market and it enables the sharing of knowledge among industry peers and also triggers meaningful networking.”

He further added that the conference further gave the forum for the IOCs and independents to understand what producing nations expect from them and also provides an umbrella for cooperation amongst various stakeholders.

Later the Ghanaian delegation led by Ms Heather Byrnes who also doubles as the Senior Commercial Officer at the United States of America’s Embassy in Accra, was hosted by some of the Ghanaian based United States (US) companies including Schlumberger, Baker Hughes, and MODEC International LLC.

At Western Geco, a subsidiary of Schlumberger, the Ghanaian delegation which was led by Mr Emmanuel Armah Kofi-Buah and supported by the Chief Executive Officer of the Petroleum Commission, Dr Kwabena Donkor, was taken through some of the company’s operations with regard to information technology and data management.

According to Rick Johnston, one of the company’s senior personnel, Schlumberger was into three key activities including Drilling, Production and Reservoir Characterisation. The forty-five minutes tour ended up with a launch and later with dinner.

This year’s conference was highly participated by almost all the major international oil companies and big independents such as: Shell, Exxon Mobil, Noble Energy, Marathon Oil Corporation, China petroleum Technology & Development Corporation, Nigeria Sao Tome & Principe Joint Development Authority, Tullow Oil, ERHC Energy, Afren, Kosmos Energy, MEPS – First Oil and Enventure Global Technology.

Also financial institutions such as Ecobank – a Pan-African with footprints in more than 32 African countries and a great degree of industry big players, decision makers and government representatives were present at the event.

From Ghana were about fifty local companies which participated. These were the Ghana National Petroleum Company (GNPC), Association of Ghana Industries, Allied Oil Company Limited, Attok International Ghana Limited, Centre for Professional System and Service, Cicada Consulting Limited, Cigads Security & Allied Services, Consolidated Shipping Agencies Ltd as well as Dalpha Ghana Limited.

Others were Folksworld Consulting Services, Geoquaye Company Ltd, Keness Ventures, Macro Group, Meridian Logistics & Supply Ltd, Nexans Kablemetal Ghana Ltd, Proconsult Ltd, Regency Alliance Insurance Ltd, SAL Consult Ltd, Sage Petroleum Ltd, Schlumberger Ghana, Seaweld Engineering Ltd, Stable Capital Ltd, STMC Global Ghana, Top Oil Company Ltd, Unity Oil Company Ltd Venture-G Travels Ltd, Walkdav Business Ventures and Zodiac Marine Services Limited.

With a retinue of seasoned speakers from the industry and governments presenting unique papers and representations from countries such as Ghana, Nigeria, Senegal, Gabon, Equatorial Guinea, South Sudan, and others made the event to be resourceful and colourful.

At the end of the event participants, exhibitors, sponsors, media partners expressed the optimism of looking forward to another fruitful mix in the 6th annual sub-Saharan Africa Oil & Gas Conference which has been scheduled to be held in Houston, Texas from Thursday April 25 – Friday April 26, 2013.

The theme for the 2013 edition will be “Maximizing Exploration & Production through Technology, Financing, Project Management, and Risk Aversion & Local Content Policy.”

The industry faces multiple crises as budgets are squeezed and tough scientific challenges loom.

Academics and patients’ groups are concerned we will not have the drugs necessary to treat future ills.

Last year, the World Health Organization’s director general, Margaret Chan, warned that the world was heading for a “post-antibiotic era”.

She raised fears that many common infections might no longer have a cure and could once again “kill unabated”.

Major problems, Dr Chan suggested, included growing resistance to antibiotics.

And as the population ages, many of us will battle with neurological conditions such as Alzheimer’s and Parkinson’s, where new drugs are also lacking.

But the old model of drug discovery is no longer working well.

This so-called blockbuster method – which commits large sums of money to finding a drug that promises to treat a huge proportion of the population, and generate swathes of cash to cover other experimental losses – can no longer sustain the industry.

The model is inefficient. Nine times out of 10, molecules which show promise at the early stage are destined for failure at later trials.

Pharmaceutical companies are also under pressure as patents for some of their most lucrative drugs expire.

Manufacturers face an uphill struggle with science too. Some argue that in its most successful years, the big pharmaceutical firms picked off the “low-hanging fruit” – the compounds that were easiest to discover and turn into drugs.

Chas Bountra, professor of translational medicine at Oxford University, says: “We don’t understand enough about human disease or enough about the mode of action of existing drugs. Take paracetamol for example. We all take it but we don’t know how it works, we don’t know what the site of action of paracetamol is.

“So if we don’t know that, how can we design better, more superior molecules?”

But finding new targets – proteins in the body that could be modified by a drug to help relieve disease – is like a lottery, he says.

“There are more than 20,000 proteins in the human body, and any of those proteins could be a target for drug discovery. Our ability, even in 2012, to be able to say one protein is going to work in this patient group or subset of patients is appalling.”

Alongside many other people working on drug development, he points to another difficulty that threatens the process – duplication.

“We don’t publish our failures, or if we do publish them, we publish too late. As a consequence other academics, other companies, carry on working on the same target, carry on wasting resources and careers and exposing patients to molecules that have a chance of failure,” Prof Bountra says.

But Prof Patrick Vallance, president of pharmaceuticals research and development at GlaxoSmithKline, thinks the industry is becoming more open: “One of the things we have done is to be very public about when things go into the clinic.

“And we publish our results – we make our protocols available to reviewers when papers are submitted. Those sorts of things help to start better visibility of what is in the pipeline.”

GlaxoSmithKline has put 13,500 structures which have the potential to kill malaria into the public domain.

Prof Vallance says the firm has done this because it is a “tough problem to crack”.

He adds: “Why not let everyone have a look at those compounds and see if they can think of something smarter than we are doing, and see if they can group them in a certain way or spot a pattern we have missed?”

But, he argues, we have to be realistic about this. “There will always be a degree of duplication, because that comes with the competition.”

Prof Bountra’s group at Oxford has also made a decision to publish all their successes and failures.

Prof Paul Workman at the Institute of Cancer Research points to another pressing issue: “With the problems of the financial crisis there has developed something of a vacuum that many of us describe as ‘the valley of death’.

“This is the valley between basic research and innovation on the one hand, and patient benefit and commercial success on the other, with this chasm in between into which there is a lack of funding and a lot of failure.”

One possible solution is for charitable foundations such as the Wellcome Trust to offer funding to fill this gap.

Prof Workman, on the other hand, works on a model where many processes of drug discovery and development come under one roof.

“We go all the way from discerning a new biological concept to developing the chemicals that block a certain pathway or gene function, and then all the way into clinical trials,” he says.

He points out that they don’t do the whole thing alone, often partnering with smaller and larger companies in later stages.

Prof Workman is optimistic that the science is moving forward, and bringing new chances of success with it: “The science is taking us in the opposite direction to blockbuster drugs, to personalised medicine. You would identify the patient who would benefit from what drug according to a gene test.

“A relatively small number of patients will benefit but they will benefit extremely well.”

What all these newer models of drug development have in common, it seems, is collaboration – perhaps presenting a cultural change for an industry that many people believe has had competition at the centre of its working.

But, says Prof Vallance, while there is need for more collaboration in the early stages of drug development for some of the more complex diseases that will turn into competition at a later point.

“There will be fierce competition to get the best drug first, to make sure you do the right trial and show you’ve got the best medicine.”—BBC

Key facts

• Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008 (1).
• Lung, stomach, liver, colon and breast cancer cause the most cancer deaths each year.
• The most frequent types of cancer differ between men and women.
• About 30% of cancer deaths are due to the five leading behavioral and dietary risks: high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, alcohol use.
• Tobacco use is the most important risk factor for cancer causing 22% of global cancer deaths and 71% of global lung cancer deaths.
• Cancer causing viral infections such as HBV/HCV and HPV are responsible for up to 20% of cancer deaths in low- and middle-income countries.
• About 70% of all cancer deaths in 2008 occurred in low- and middle-income countries.
• Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1 million deaths in 2030 (2).

Cancer is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumours and neoplasms. One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjoining parts of the body and spread to other organs. This process is referred to as metastasis. Metastases are the major cause of death from cancer.

The problem

Cancer is a leading cause of death worldwide and accounted for 7.6 million deaths (around 13% of all deaths) in 2008. The main types of cancer are:

• lung (1.37 million deaths)
• stomach (736 000 deaths)
• liver (695 000 deaths)
• colorectal (608 000 deaths)
• breast (458 000 deaths)
• cervical cancer (275 000 deaths) (3).

About 70% of all cancer deaths occurred in low- and middle-income countries. Deaths from cancer worldwide are projected to continue to rise to over 13.1 million in 2030.

What causes cancer?

Cancer arises from one single cell. The transformation from a normal cell into a tumour cell is a multistage process, typically a progression from a pre-cancerous lesion to malignant tumours. These changes are the result of the interaction between a person’s genetic factors and three categories of external agents, including:

• physical carcinogens, such as ultraviolet and ionizing radiation;
• chemical carcinogens, such as asbestos, components of tobacco smoke, aflatoxin (a food contaminant) and arsenic (a drinking water contaminant); and
• biological carcinogens, such as infections from certain viruses, bacteria or parasites.

WHO, through its cancer research agency, International Agency for Research on Cancer (IARC), maintains a classification of cancer causing agents.

Ageing is another fundamental factor for the development of cancer. The incidence of cancer rises dramatically with age, most likely due to a build-up of risks for specific cancers that increase with age. The overall risk accumulation is combined with the tendency for cellular repair mechanisms to be less effective as a person grows older.

Risk factors for cancers

Tobacco use, alcohol use, unhealthy diet and physical inactivity are the main cancer risk factors worldwide. Chronic infections from hepatitis B (HBV), hepatitis C virus (HCV) and some types of Human Papilloma Virus (HPV) are leading risk factors for cancer in low- and middle-income countries. Cervical cancer, which is caused by HPV, is a leading cause of cancer death among women in low-income countries.

How can the burden of cancer be reduced?

Knowledge about the causes of cancer, and interventions to prevent and manage the disease is extensive. Cancer can be reduced and controlled by implementing evidence-based strategies for cancer prevention, early detection of cancer and management of patients with cancer. Many cancers have a high chance of cure if detected early and treated adequately.

Modifying and avoiding risk factors

More than 30% of cancer deaths could be prevented by modifying or avoiding key risk factors, including:

• tobacco use
• being overweight or obese
• unhealthy diet with low fruit and vegetable intake
• lack of physical activity
• alcohol use
• sexually transmitted HPV-infection
• urban air pollution
• indoor smoke from household use of solid fuels.

Tobacco use is the single most important risk factor for cancer causing 22% of global cancer deaths and 71% of global lung cancer deaths. In many low-income countries, up to 20% of cancer deaths are due to infection by HBV and HPV.

Prevention strategies

• Increase avoidance of the risk factors listed above.
• Vaccinate against human papilloma virus (HPV) and hepatitis B virus (HBV).
• Control occupational hazards.
• Reduce exposure to sunlight.

Early detection

Cancer mortality can be reduced if cases are detected and treated early. There are two components of early detection efforts:

Early diagnosis

The awareness of early signs and symptoms (for cancer types such as cervical, breast colorectal and oral) in order to get them diagnosed and treated early before the disease becomes advanced. Early diagnosis programmes are particularly relevant in low-resource settings where the majority of patients are diagnosed in very late stages and where there is no screening.

Screening

Screening is defined as the systematic application of a test in an asymptomatic population. It aims to identify individuals with abnormalities suggestive of a specific cancer or pre-cancer and refer them promptly for diagnosis and treatment. Screening programmes are especially effective for frequent cancer types for which a cost-effective, affordable, acceptable and accessible screening test is available to the majority of the population at risk.

Examples of screening methods are:

• visual inspection with acetic acid (VIA) for cervical cancer in low-resource settings;
• PAP test for cervical cancer in middle- and high-income settings;
• mammography screening for breast cancer in high-income settings.

Treatment

Cancer treatment requires a careful selection of one or more intervention, such as surgery, radiotherapy, and chemotherapy. The goal is to cure the disease or considerably prolong life while improving the patient’s quality of life. Cancer diagnosis and treatment is complemented by psychological support.

Treatment of early detectable cancers

Some of the most common cancer types, such as breast cancer, cervical cancer, oral cancer and colorectal cancer have higher cure rates when detected early and treated according to best practices.

Treatment of other cancers with potential for cure

Some cancer types, even though disseminated, such as leukemias and lymphomas in children, and testicular seminoma, have high cure rates if appropriate treatment is provided.

Palliative care

Palliative care is treatment to relieve, rather than cure, symptoms caused by cancer. Palliative care can help people live more comfortably; it is an urgent humanitarian need for people worldwide with cancer and other chronic fatal diseases. It is particularly needed in places with a high proportion of patients in advanced stages where there is little chance of cure.

Relief from physical, psychosocial and spiritual problems can be achieved in over 90% of advanced cancer patients through palliative care.

Palliative care strategies

Effective public health strategies, comprising of community- and home-based care are essential to provide pain relief and palliative care for patients and their families in low-resource settings.

Improved access to oral morphine is mandatory for the treatment of moderate to severe cancer pain, suffered by over 80% of cancer patients in terminal phase.

WHO response

In 2008, WHO launched its Noncommunicable Diseases Action Plan which includes cancer-specific interventions.

WHO and the International Agency for Research on Cancer (IARC), the specialized cancer research agency of WHO, collaborate with other United Nations organizations and partners to:

• increase political commitment for cancer prevention and control;
• coordinate and conduct research on the causes of human cancer and the mechanisms of carcinogenesis;
• develop scientific strategies for cancer prevention and control;
• generate new knowledge, and disseminate existing knowledge to facilitate the delivery of evidence-based approaches to cancer control;
• develop standards and tools to guide the planning and implementation of interventions for prevention, early detection, treatment and care;
• facilitate broad networks of cancer control partners and experts at global, regional and national levels;
• strengthen health systems at national and local levels to deliver cure and care for cancer patients; and
• provide technical assistance for rapid, effective transfer of best practice interventions to developing countries.—WHO